Spring Creek Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Spring Creek Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-372,000	Closed	-$68.3M	–	666
2021 Q2	$68.3M	Sell	372,000 -190,923	-34%	-$32.8M	3.39%	4
2021 Q1	$86.1M	Buy	562,923 +386,923	+220%	+$59.9M	3.72%	5
2020 Q4	$27.5M	Buy	+176,000	New	+$22.6M	2.02%	9

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Spring Creek Capital's ALXN Position: Q3 2021 in Review

Spring Creek Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 372,000 shares — an estimated $68.3M sold.

Spring Creek Capital first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $86.1M in Q1 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Spring Creek Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Spring Creek Capital sold 372,000 Alexion Pharmaceuticals shares in Q3 2021, an estimated $68.3M.
Spring Creek Capital first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
Spring Creek Capital's Alexion Pharmaceuticals position peaked at $86.1M in Q1 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Spring Creek Capital's 13F filing for Q3 2021, filed 15 Nov 2021.